Spinal Deformity in Metabolic Disorders


Disorder and OMIM link

Pathophysiology and inheritance

Typical features

Treatment

Association with spinal deformity

Rickets like disorders
    
Vitamin D-deficient rickets

Vitamin D deficiency from poor dietary intact, often breastfed, dark-skinned

Widened physes, lethargy, limb deformities

Physiological doses of vitamin D and calcium

Historically believed to be a strong etiological factor in scoliosis. Spinal deformity will occur in bipedial rats on a rachetogenic diet [8]. Human scoliosis is rarely if ever caused by dietary deficiency rickets [7]

Vitamin D-dependent rickets

#264700 (Type I)

#277440 (Type II)

%600785 (Type II with normal vitamin D receptor)

#193100 (autosomal dominant type)

Type I – AR, 12q13; genetic deficiency of enzyme 1-alpha-hydroxylase

Type II – abnormality of calcitriol receptor; end-organ resistance

Type I – low levels 1,25(OH)2 vitamin D

Type II – increased levels 1,25(OH)2 vitamin D; severe hypocalcemia

Type I – Calcitriol

Type II – Calcitriol, calcium

Spinal deformity rarely associated, possibly because of decreased growth velocities

X-linked hypophosphatemic rickets

#307800

Autosomal dominant

#193100

X-linked dominant, PHEX gene, Xp22 coding for a protease

AD, FGF23 gene, 12p13

Hypophosphatemia, decreased levels 1,25(OH)2 vitamin D;

normal calcium

Calcitriol; phosphate

Spinal deformity rarely associated, possibly because of decreased growth velocities

Lowe’s syndrome

#309000

Mutation in OCRL1 gene; Xp26; deficiency of phosphatidylinostitol 4,5-biphosphanate 5-phosphatase

Phosphaturia, hypophosphatemic rickets; aminoaciduria; decreased ammonia production by kidney – acidosis; carnitine wasting; cataracts; MR

Replacement therapy – phosphate, carnitine, alkali; supportive care

May develop increased lordosis and occasionally scoliosis [14]

Hypophosphatasia

#241500 (infantile)

#241510 (childhood)

#146300 (adult and odonthypophosphatasia forms)

Defect in alkaline phosphatase production

Identified in perinatal, infantile, childhood, adult, and odontohypophosphatasia forms. Perinatal hypophosphatasia lethal. Infantile form has a roughly 50 % mortality rate with symptoms appearing within the first 6 months after birth. The other forms are generally nonlethal. Adult form and odontohypophosphatasial form are marked by premature teeth loss. Common symptoms include bone malformations and higher chance of bone fracture
 
Isolated cases reports of scoliosis in infantile form [11, 15]. Suggested as a genetic linkage rather than a common etiology [12]

Osteogenesis imperfecta

Over 100 different mutations lead to OI

Incidence 1:10–20,000
  
Type I OI

166240 (IA), #166200 (IB)

AD. COL1A1 (chromosome 17) or COL1A2 (chromosome 7) functional null alleles causing reduced amounts of normal collagen I

Mildest and most common form of OI. Blue sclera, conductive hearing loss, with or without dentigenesis imperfecta

Bisphosphonate treatment currently with either pamindronate or alendronate for more severe cases

Occurrence of scoliosis is related to the severity of bone involvement

Type II OI

166210

Typically new mutation in either the COL1A1 gene or the COL1A2 gene

Fatal perinatally with intrauterine fractures, intracranial hemorrhage
 
Fatal too early for scoliosis

Type III OI

#259420

AD, rarely AR. Mutation in most cases lies in one of the genes for type I collagen, COL1A1 or COL1A2

One-eighth as common as type I. Severe involvement with progressive deformities, dentigenesis imperfecta, hearing loss, easy bruising, triangular facies

Bisphosphonate treatment currently with either pamindronate or alendronate

Scoliosis is very common. Kyphosis may also occur but is less common

Type IV OI

#166220

AD. COL1A1 or COL1A2

Similar to type I without blue sclera and more severe osseous involvement

Bisphosphonate treatment currently with either pamindronate or alendronate

Similar to type III

Type V OI

%610967

AD. Rare. Uncertain molecular mechanism

[12, 16] Similar to type V but with hyperplastic callus formation at fracture sites, calcification of the interosseous membrane between the radius and ulna, and the presence of a radio-opaque metaphyseal band adjacent to the growth plates

Bisphosphonate treatment currently with either pamindronate or alendronate

Similar to type III

Type VI OI

%610968

AD with parental mosaicism. Rare. Uncertain molecular mechanism

[17] Similar to type IV

Bisphosphonate treatment currently with either pamindronate or alendronate

Similar to type III

Type VII OI

#610682

Eight affected individuals in a small consanguineous First Nations community in northern Quebec. Mutation in the CRTAP gene (also cause type IIB)

Bone fragility and low bone mass

Uncertain

Uncertain

Type VIII OI

#610915

AR. Mutation in the gene encoding leprecan (LEPRE1)

Lethal

Uncertain

Uncertain.

Type IX OI

#259440

AR. Abnormality in PPIB gene

Lethal

Uncertain

Uncertain

Type X OI

#613848

AR. Mutation in the serpin peptidase inhibitor (SERPINH1)

Lethal

Uncertain

Uncertain

Type XI OI

#610968

AR. Homozygous mutation in the FKBP10 gene

Severe OI without dentogenesis imperfecta

Uncertain

Scoliosis in 5/8 reported patients

Type XII OI

#613849

AR. Mutation in the SP7 gene

Milder deformity without dentogenesis imperfecta. White sclera

Uncertain

Scoliosis reported

Type XIII OI

#614856

AR. Homozygous mutation in the BMP1 gene

Variable

Uncertain

Kyphoscoliosis (in some patients). S-curve scoliosis of thoracic and lumbar spine (in some patients)

Type XIV OI

#615066

AR. Homozygous mutation in the TMEM38B gene

Variable

Uncertain

Uncertain

Type XV OI

#615220

AR. Homozygous or compound heterozygous mutation in the WNT1 gene

More severe, blue sclera

Uncertain

Scoliosis reported

Other osteopenic syndromes
    
Bruck syndrome #259450

Rare. Possibly gene encoding bone telopeptidelysyl hydroxylase

Bone similar to type I OI, multiple joint contractures, severe scoliosis [1618]

Uncertain

Severe scoliosis similar to OI type III

Osteoporosis-pseudoglioma syndrome #259770

Familial gene encoding low-density lipoprotein receptor-related protein-5

Blindness. Brittle bones

Uncertain

Scoliosis is reported

Idiopathic juvenile osteoporosis #259750

Uncertain etiology

Idiopathic osteoporosis which resolves with adolescence

Uncertain. Protect spine

May develop spine compression fractures





















































Selected Mucopolysaccharidoses

Mucopolysaccharidoses

Pathophysiology

Typical features

Treatment

Association with spinal deformity

Type I (Hurler’s syndrome)

#607014

Gene encoding alpha-l-iduronidase

Course features are evident early. Bulging fontanels, neurological compression, corneal clouding; upper airway obstruction; pulmonary edema postoperative; short stature; carpal tunnel

Bone marrow transplant

Enzyme therapy may help

? Gene therapy

Gibbus deformity lower spine. Upper cervical instability, odontoid hypoplasia and compression from instability or dural and ligamentous hypertrophy may occur

Type II (Hunter syndrome)

+309900

Deficient activity of iduronate 2-sulfatase

X-linked; mapped to Xq27–28

Dx: Enzyme assays in cultured fibroblasts/leukocytes

Increased urinary heparan and dermatan sulfate

Two forms exist

(Type A – severe; Type B – mild)

Type A – clinical features as in Type IH; onset age 1–2 years; death in adolescence, third decade

Type B – may be diagnosed in adulthood

Course facial features; hearing loss; mental retardation (Type A); absence of corneal clouding; upper airway obstruction; pulmonary edema postoperative; HSM; dysostosis multiplex; short stature; HCP; carpal tunnel; ivory skin lesions; Mongolian spots; hypertrichosis

Bone marrow transplant

Enzyme therapy may alter disease progression; not curative

Idursulfase

? Gene therapy

Similar to other mucopolysaccharidosis (MPS)

Type III (Sanfilippo syndrome)

#252900

#252920

#252930

#252940

Type A – deficiency of heparin N-sulfatase (17q25.3)

Type B – deficiency of alpha-N-acetylglucosaminidase (17q21)

Type C – deficiency of aceyl-CoA:alpha-glucosaminide acetyltransferase (14)

Type D – deficiency of N-acetylglucosamine-6-sulfatase (12q14)

Dx: Increased urinary heparan sulfate

Type A – most severe, aggressive

Behavioral issues at 2 years, neurological manifestations at 6 years

Death in second decade

Corneal clouding not a common finding; attentional/behavioral problems; hyperactivity; seizures; diarrhea; URI

Supportive care

Not improved by bone marrow transplant

Similar to other MPS

Type IV (Morquio syndrome)

Numerous types

Type A – deficiency of galactosamine-6-sulfatase (GALNS gene, 16q24.3)

Type B – β-galactosidase (GLB1 gene, 3p21.33)

Increased urinary excretion of keratin sulfate (cartilage/cornea) mild may not excrete

ELISA

Enzyme assay in cultured fibroblasts/leukocytes

Genetic testing to detect mutations in GALNS, GLB1

Clinically, both forms may be similar; great variability in severity within both groups

Mortality related to atlantoaxial instability, myelopathy and pulmonary compromise

For severe, death in second or third decade of life

No course facial features; normal intelligence; spondyloepiphyseal dysplasia; ligamentous laxity; odontoid hypoplasia; shortened trunk dwarfism; genu valgus; greater incidence of spinal involvement; bowel/bladder incontinence; OSA; pulmonary infections – chest wall deformity; heart valve thickening/defects; corneal clouding; enamel

Less common – hearing loss, hernias

Supportive treatment

Similar to other MPS. These patients survive long enough that orthopedic treatment, particularly for cervical instability may be necessary

Type VI (Maroteaux–Lamysynd)

#253200

AR

Deficiency of N-acetylgalactosamine 4-sulfatase

Accumulation of dermatan sulfate

Acceleration in growth during first year; followed by regression and short stature; course features, HSM, corneal clouding; normal intelligence

Other: hearing loss, respiratory infections, valvular disease

Bone marrow transplant reported as successful. Enzymatic treatment approved

Similar to other MPS

Type VII (Sly disease)

#253220

Deficiency of β-glucoronidase, required for degradation of dermatan sulfate, heparin sulfate, and chondroitin sulfate

Mutation in gene mapped to chromosome 7

Phenotype varies; severe form (subtype 1) present at birth – jaundice, anemia, hydrops; milder forms present later, before (subtype 2) or after (subtype 3) age 4 years; course features; HSM; hernias; MR; dysostosis multiplex

Bone marrow transplant reported as successful in improving daily function but not the mental retardation

Similar to other MPS



Pulmonary failure is the leading cause of death in adults with OI, and it is closely associated with thoracic scoliosis. Widmann et al. [19] found a high negative correlation between pulmonary function and thoracic scoliosis and but not with chest wall deformity or kyphosis. They also found diminution in vital capacity below 50% in thoracic curve of 60° or more.

Spinal deformity in OI is directly related to the severity of osseous involvement [2022], though body weight is also a factor in bone density [23]. Anissipour et al. [20] recently evaluated progression of scoliosis in a large cohort of patients with various types of OI and found the most rapid progression in the more severe type III. While ligamentous laxity, also from type I collagen deficiency, may also contribute, a series of patients with various types of OI found less scoliosis in those with ligamentous laxity [21]. There is a tendency for later development of scoliosis in those with early development of motor milestones, particularly supported sitting [21]. Overall, the worse the osseous involvement in terms of intrinsic vertebral body deformity and decreased Z-scores for bone density, the worse the scoliosis and the more difficultly achieving good fixation for correction [22, 23]. The morphology of the vertebral bodies ranges from normal contours to flattened, wedged, and biconcave with the biconcave vertebra more likely to develop severe scoliosis [2325]. Six or more biconcave vertebra before puberty appears prognostic of developing scoliosis of greater than 50° [23]. The spine may also become kyphotic particularly [26] in those with more severe involvement [27]. Cervical fractures [28] including spontaneous paraplegia from chiropractic manipulation [29], thoracic fractures with spinal cord injury [30], and multiple flexion stress endplate fractures of the thoracic and lumbar spine [31] have been reported. Daivajna et al. [32] reported a modified anterolateral approach for decompression of myelopathy from severe cervical kyphosis in a 9-year-old with OI.

Bracing has been attempted for spinal deformity from OI. However, the corrective force applied through the pathological ribs only leads to further rib deformity and may contribute to worsening pulmonary function [3335]. Current braces cannot achieve this. Patients who are not operative candidates can be fitted with custom seating for comfort and function [36, 37]. Bracing’s role in OI is primarily limited to postoperative temporary support though there is some suggestion that an orthosis can slow the progression of basilar impression [3].

Positioning patients for surgery can be very difficult and must be carefully supervised because of chest wall deformities, fragile extremities, ribs, and frequent contractures. Unpadded blood pressure cuffs can result in fractures. Surgery for these patients should typically occur in institutions accustomed to their care [38]. Fatality has been reported from intraoperative rib fractures [39]. Classically, correcting curves in severely soft bone has been difficult at best with most authors recommending stabilization rather than relying upon correction [34]. The stability of fixation depends upon both the strength of the bone and the quality of the fixation’s purchase. Polymethylmethacrylate has been used for additional fixation [33, 40, 41]. Historically, each new type of fixation has been attempted. As might be expected, the greater the purchase and the more segmental the fixation, the less stress required on any single level and the greater the correction achieved [42] (Figs. 19.1a–c and 19.2a–d). Preoperative halo gravity traction using multiple pins may be useful [43, 44] though both sixth and fourth nerve palsies have been reported in OI patients [45]. Postoperatively, there is little change from preoperative ambulatory ability or activity [34, 37, 46], though patients report less pain, fatigue, and dyspnea [47], and the improvements gained at surgery are usually maintained into adulthood [43, 47]. Spondylolysis [48] or an elongated pars with spondylolysthesis [49] can occur below a long spinal fusion. Anterior interbody fusion has been described [49], but the spondylolisthesis may not be symptomatic (Fig. 19.3).
Sep 22, 2016 | Posted by in NEUROSURGERY | Comments Off on Spinal Deformity in Metabolic Disorders

Full access? Get Clinical Tree

Get Clinical Tree app for offline access